Contact your trial team or GP promptly if you experience: Persistent or severe nausea, vomiting, or diarrhoea that prevents adequate fluid or food intake Signs of dehydration, such as dizziness, dark urine, or reduced urination Severe or persistent abdominal pain, which may rarely indicate pancreatitis a known risk with GLP-1 receptor agonist therapies or gallbladder problems [18] [21] Rapid or irregular heartbeat (palpitations) Significant injection site reactions, including signs of infection (redness, warmth, swelling, or discharge) Symptoms of low blood sugar (hypoglycaemia) if you are also taking insulin or a sulfonylurea, such as shakiness, sweating, or confusion If you are unsure whether your symptoms require urgent attention, contact NHS 111 (by phone or online at 111.nhs.uk) for advice
Retrieved from GLP-1 Medications and Hair Loss
The main difference
Most patients find that after 4 to 6 weeks, hunger levels decrease significantly, making it easier to manage portion sizes and reduce overeating
2023, www.uptodate.com/contents/glucagon-like-peptide-1-based-therapies-for-the-treatment-of-type-2-diabetes-mellitus/print?search=tirzepatide&source=search_result&selectedTitle=1~5&usage_type=default&display_rank=1
Eliminate any that cannot provide batch-specific analytical documentation or refuse video tours